On Friday, CADTH’s Pharmaceutical Reviews Update – Issue 43 introduced a number of updates pertaining to its Reimbursement Reviews procedures. These include:
Budget Impact Analysis (BIA) Consultation: CADTH is seeking stakeholder feedback on its draft BIA template tool. The tool is an optional resource to ... Read More
News & Events
31
Jan2024
20
Dec2023
PDCI released a new issue of PDCI Market Access INSIGHTS, featuring research and opinion on the evolving state of private health insurance in Canada.
In this Issue:... Read More
19
Dec2023
As another memorable year draws to a close, the team at PDCI Market Access would like to express its sincere gratitude and appreciation for all our clients, partners, and people who support us in our purpose to improve health outcomes for all.We hope your holiday season is filled ... Read More
14
Nov2023
First Step of The New Guidelines Consultation Announced
On October 25, 2023, the Patented Medicine Prices Review Board (PMPRB) released details on the first of its two-step consultation process for developing its new set of price regulatory guidelines. PMPRB will send invitations to stakeholders for ... Read More
13
Nov2023
On November 10, 2023, the Patented Medicine Prices Review Board (PMPRB) launched first phase of its consultation process towards development of new price regulatory Guidelines. PMPRB published its Scoping Paper for the Consultations on the Board’s Guidelines and invited feedback to be provided either ... Read More
02
Oct2023
On September 27, 2023, the Patented Medicine Prices Review Board (PMPRB) published its final decision regarding the Amended Interim Guidance first proposed on June 20, 2023.Effective immediately, the proposed amendments to the Interim Guidance are implemented without changes, notwithstanding the concerns raised by many of the ... Read More
08
Sep2023
Mississauga, ON - September 11, 2023 – Canada’s leading biopharmaceutical pricing and reimbursement consultancy, PDCI Market Access (PDCI), a division of McKesson Canada, today announced the appointment of three leaders, Nabil Tadros, Andrea Lau and John-Paul Dowson to further enhance the company’s capabilities in delivering high-quality services and ... Read More
05
Sep2023
On September 5, 2023, the pan-Canadian Pharmaceutical Alliance (pCPA) announced the appointment of Douglas Clark as its first CEO, effective September 11, 2023. Clark was Executive Director of the Patented Medicine Prices Review Board (PMPRB) for almost a decade before he resigned from that position earlier this year.... Read More
03
Aug2023
PCPA Seeks Stakeholder Input On Its Proposed Process To Implement CADTH Time-Limited Recommendations
/ News, pCPA, What's New
The pan-Canadian Pharmaceutical Alliance (pCPA) introduced its proposed pCPA Temporary Access Process (pTAP) and invited stakeholders’ input on the process, its principles and conditions by August 18th, 2023.
The proposed pTAP and its associated principles are intended to inform pCPA negotiations and product listing agreements for ... Read More
11
Jul2023
On June 6, 2023, the Patented Medicine Prices Review Board (PMPRB) released its first NEWSletter of 2023, providing updates on recent activities among the Board and Board staff. Updates from the NEWSletter and PDCI’s insights on potential implications are summarized below. Despite recent quietness from PMPRB on its ... Read More